Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel

Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC)

(2017) S. Gluck et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-agent nab-paclitaxel given weekly (3/4) as first-line therapy for metastatic breast cancer (an International Oncology Network study, #I-04–012)

(2017) B. Mirtsching et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC)

(2017) S. J. Vukelja et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine and ABI-007 chemotherapy as neoadjuvant treatment of locally advanced breast cancer

(2017) A. Veerapaneni et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer

(2017) M. A. Danso et al.   JOURNAL OF CLINICAL ONCOLOGY

Nab-paclitaxel Efficacy in the Orthotopic Model of Human Breast Cancer Is Significantly Enhanced By Concurrent Anti–Vascular Endothelial Growth Factor A Therapy

(2015) Lisa D. Volk et al.   NEOPLASIA

A Phase II Neoadjuvant Trial of Sequential Nanoparticle Albumin-Bound Paclitaxel Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide in Locally Advanced Breast Cancer

(2010) André Robidoux et al.   Clinical Breast Cancer

An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers

(2009) Agnieszka K. Witkiewicz et al.   AMERICAN JOURNAL OF PATHOLOGY

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

(2009) George Dranitsaris et al.   BREAST CANCER RESEARCH AND TREATMENT

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Significantly Longer Progression-Free Survival Withnab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

(2009) William J. Gradishar et al.   JOURNAL OF CLINICAL ONCOLOGY

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

(2009) Stephen Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane(R)) in combination with gemcitabine in patients with metastatic breast cancer (N0531)

(2008) V. Roy et al.   ANNALS OF ONCOLOGY

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

(2008) Neil P. Desai et al.   ANTI-CANCER DRUGS

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype

(2008) S E Elsheikh et al.   BRITISH JOURNAL OF CANCER

Taxanes as primary chemotherapy for early breast cancer

(2008) Federica Cuppone et al.   CANCER

Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer

(2008) Martine J. Piccart-Gebhart et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

(2008) Priya Rastogi et al.   JOURNAL OF CLINICAL ONCOLOGY